Soleno Therapeutics (SLNO) EPS (Weighted Average and Diluted) (2016)
Historic EPS (Weighted Average and Diluted) for Soleno Therapeutics (SLNO) over the last 3 years, with Q2 2016 value amounting to -$0.07.
- Soleno Therapeutics' EPS (Weighted Average and Diluted) fell 12951.91% to -$0.07 in Q2 2016 from the same period last year, while for Jun 2016 it was -$0.74, marking a year-over-year increase of 5155.61%. This contributed to the annual value of -$4.38 for FY2024, which is 8559.32% down from last year.
- According to the latest figures from Q2 2016, Soleno Therapeutics' EPS (Weighted Average and Diluted) is -$0.07, which was down 12951.91% from $0.25 recorded in Q2 2015.
- In the past 5 years, Soleno Therapeutics' EPS (Weighted Average and Diluted) registered a high of $0.25 during Q2 2015, and its lowest value of -$5.21 during Q2 2014.
- In the last 3 years, Soleno Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.07 in 2016 and averaged -$1.68.
- As far as peak fluctuations go, Soleno Therapeutics' EPS (Weighted Average and Diluted) surged by 10479.85% in 2015, and later crashed by 12951.91% in 2016.
- Quarter analysis of 3 years shows Soleno Therapeutics' EPS (Weighted Average and Diluted) stood at -$5.21 in 2014, then soared by 104.8% to $0.25 in 2015, then plummeted by 129.52% to -$0.07 in 2016.
- Its EPS (Weighted Average and Diluted) was -$0.07 in Q2 2016, compared to $0.25 in Q2 2015 and -$5.21 in Q2 2014.